Our Commercial team is responsible for all the Association’s work on the Value & Access imperatives and all commercial issues, i.e. all aspects of a medicine's life from the granting of a licence/marketing authorisation onwards.
This extended analysis was authored by Colette Goldrick, ABPI Director of NHS Engagement, in response to today's (5 April) House of Lords Long-Term Sustainability of the NHS Committee report.Read more
On 7 January 2015, the National Institute for Health and Care Excellence (NICE) issued a draft clinical practice guideline on the management of type 2 diabetes by the NHS in England and Wales.Read more
Today sees the launch of a new ABPI quick start reference guide on Joint Working which has been developed in response to feedback gathered from our members and NHS partners. Read more
Today we published our response to the GMC consultation on 'Good practice in prescribing and managing medicines and devices'.Read more
We are delighted to announce our second one day ABPI Masterclass on PPRS, taking place on 10 June at the Royal Society, SW1.
We are delighted to announce our first one day ABPI Masterclass on PPRS, taking place on 16 May at the Royal Society, SW1. Read more
Today’s front page story in the Daily Telegraph “Patients are denied high cost drugs by NHS trusts” raises new concerns about an on-going problem – how to improve patient access to new innovative medicines in the NHS.Read more
Value based pricing will be introduced into the UK from January 2014 and is expected to be one of the biggest reforms to the pricing of new medicines in the UK since the Pharmaceutical Price Regulation Scheme was set up more than 50 years ago. Read more